Navigation Links
Bullet Bio Provides Update On Recent Financing And Results From Proof-Of-Concept Study For Lead Product Candidate
Date:9/12/2013

MENLO PARK, Calif., Sept. 12, 2013 /PRNewswire/ -- Bullet Biotechnology, Inc., a company developing an active immunotherapy for B-cell lymphomas, announced that it completed the final close of its Series A financing in June, bringing the total amount raised since the company's founding in September 2011 to approximately $2.5 million. The additional Series A funding will be used to support additional preclinical research and to further prepare the company's active immunotherapy for an Investigational New Drug (IND) application. 

The company also announced that preliminary in-vivo data from a study of several of its active immunotherapy product candidates in tumor-bearing mice demonstrated a significant survival advantage over control vaccinations.  After reviewing the results, Ronald Levy, MD, Bullet Bio Clinical Advisory Board Member, said, "This animal experiment is very encouraging for Bullet's technology.  It suggests that the Bullet idiotype vaccine is superior to the previous 'gold standard.'"

Bullet Bio's study using the 38C13 mouse model of lymphoma was conducted by Aragen Bioscience, Inc., headquartered in Morgan Hill, CA.  In addition to the in-vivo proof of concept studies, Aragen also conducted the initial manufacturing process development and product characterization of Bullet Bio's idiotype vaccine.  Bullet Bio and Aragen are continuing to further develop manufacturing and analytical methods for Bullet Bio's vaccine in preparation for clinical trials. Bullet Bio is continuing to analyze the results of the study while aggressively moving forward with Aragen on further preclinical in-vivo and in-vitro studies as manufacturing methods are prepared for clinical trials. 

"I am very excited with our progress and with the investors we've added to the Bullet Bio family. Our vision is a world where patients have better options, where a finely targeted, personalized immunotherapy can be used instead of the carpet-bombing chemotherapy approach. We're working very hard to start clinical trials in 2015 to demonstrate the safety and efficacy of our product and ultimately get to patients as quickly as we can," said Willie Quinn, President & CEO of Bullet Bio.

About Active Immunotherapy in B-Cell Lymphomas

In 2013, nearly 70,000 patients will be diagnosed in the US and Europe with incurable B-cell lymphomas, including Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma.  More than 60% of CLL patients are asymptomatic when diagnosed, and the standard of care is to observe these patients until the severity of symptoms warrants treatment. Although modern drugs, including antibodies and kinase inhibitors, improve outcomes, mortality for B-cell lymphomas remains high. Standard treatment often leads to chemotherapy and is accompanied by infection, bleeding, fatigue and other side effects.

Bullet Bio is working to develop an active immunotherapy that would be safe enough to be given to asymptomatic patients and powerful enough to change the course of their disease by harnessing the power of their own immune system.

About Bullet Biotechnology

Bullet Biotechnology, Inc. is a privately-held biotechnology company researching and developing active immunotherapies for patients with cancers and autoimmune diseases. Bullet Bio's lead product, BB-001, is a fully personalized active immunotherapy that uses a unique marker on B-cell lymphoma cells, the idiotype protein, to train a patient's own immune system to target their cancer cells.


'/>"/>
SOURCE Bullet Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Comments on Insurance Policy Bulletin
2. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
4. MetaStat Announces Stock Trading on OTC Bulletin Board
5. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
6. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
7. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
10. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
11. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Empty Capsules Market is poised to grow at a CAGR ... by 2025. This industry report analyzes the market estimates ... regional levels presented in the research scope. The study provides historical market ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... Feb. 23, 2017 Report analyzes the worldwide markets ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year ... analytics are derived from primary and secondary research. Company profiles ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated ... National Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual ... Bunkum winner is the Center for American Progress (CAP), for its report, Lessons From ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
Breaking Medicine News(10 mins):